Disease · MONDO_0005485

psychotic disorder

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. psychotic disorder. Diseases, record MONDO_0005485. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005485

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: psychotic disorder; Open Targets
Open Targets ID: MONDO_0005485; Open Targets
Other names: psychosis; Open Targets
Disease Ontology: DOID:2468; Disease Ontology
NCI Thesaurus: C78576; NCI Thesaurus
Highest stage of its drugs: Approval, for 70 of its 138 drugs, from ATC, DailyMed, EMA Human Drugs and TTD; Open Targets

Drugs138

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RISPERIDONE	CHEMBL85	Small molecule	Approval	ATC	25	24	24	Drugs and targets
ARIPIPRAZOLE	CHEMBL1112	Small molecule	Approval	ATC	19	18	18	Drugs and targets
OLANZAPINE	CHEMBL715	Small molecule	Approval	ATC	11	10	10	Drugs and targets
QUETIAPINE	CHEMBL716	Small molecule	Approval	ATC	10	9	9	Drugs and targets
PIMAVANSERIN	CHEMBL2111101	Small molecule	Approval	ATC	9	8	8	Drugs and targets
PALIPERIDONE	CHEMBL1621	Small molecule	Approval	ATC and EMA Human Drugs	7	5	5	Drugs and targets
CLOZAPINE	CHEMBL42	Small molecule	Approval	ATC	6	5	5	Drugs and targets
ZIPRASIDONE	CHEMBL708	Small molecule	Approval	ATC	6	5	5	Drugs and targets
HALOPERIDOL	CHEMBL54	Small molecule	Approval	ATC and DailyMed	6	4	4	Drugs and targets
AMISULPRIDE	CHEMBL243712	Small molecule	Approval	ATC	3	2	2	Drugs and targets

1 to 10 of 138

See all 138 drugs

Targets77

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
DRD2	D(2) dopamine receptor	45	D2-like dopamine receptor antagonist; D2-like dopamine receptor inverse agonist; Dopamine D2 receptor antagonist; Dopamine D2 receptor inhibitor; Dopamine D2 receptor modulator; Dopamine D2 receptor partial agonist; Dopamine receptor antagonist; Dopamine receptors; D2 & D3 antagonist	Approval	https://conductscience.org/library/genes/1813	Drugs and targets
HTR2A	5-hydroxytryptamine receptor 2A	32	Serotonin (5-HT) receptor antagonist; Serotonin 2 (5-HT2) receptor antagonist; Serotonin 2 receptors; 5-HT2a & 5-HT2c antagonist; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2a (5-HT2a) receptor inverse agonist	Approval	https://conductscience.org/library/genes/3356	Drugs and targets
DRD3	D(3) dopamine receptor	15	D2-like dopamine receptor antagonist; D2-like dopamine receptor inverse agonist; Dopamine D3 receptor antagonist; Dopamine D3 receptor modulator; Dopamine receptor antagonist; Dopamine receptors; D2 & D3 antagonist	Approval	https://conductscience.org/library/genes/1814	Drugs and targets
HTR2C	5-hydroxytryptamine receptor 2C	13	Serotonin (5-HT) receptor antagonist; Serotonin 2 (5-HT2) receptor antagonist; Serotonin 2 receptors; 5-HT2a & 5-HT2c antagonist; Serotonin 2c (5-HT2c) receptor agonist; Serotonin 2c (5-HT2c) receptor antagonist	Approval	https://conductscience.org/library/genes/3358	Drugs and targets
DRD4	D(4) dopamine receptor	11	D2-like dopamine receptor antagonist; D2-like dopamine receptor inverse agonist; Dopamine D4 receptor antagonist; Dopamine receptor antagonist	Approval	https://conductscience.org/library/genes/1815	Drugs and targets
NR3C1	Glucocorticoid receptor	9	Glucocorticoid receptor agonist; Glucocorticoid receptor antagonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
HTR1A	5-hydroxytryptamine receptor 1A	5	Serotonin (5-HT) receptor antagonist; Serotonin 1a (5-HT1a) receptor agonist; Serotonin 1a (5-HT1a) receptor partial agonist	Approval	https://conductscience.org/library/genes/3350	Drugs and targets
CNR1	Cannabinoid receptor 1	3	Cannabinoid CB1 receptor agonist; Cannabinoid CB1 receptor antagonist; Cannabinoid CB1 receptor negative allosteric modulator	Phase 3	https://conductscience.org/library/genes/1268	Drugs and targets
HTR2B	5-hydroxytryptamine receptor 2B	3	Serotonin (5-HT) receptor antagonist; Serotonin 2 (5-HT2) receptor antagonist; Serotonin 2b (5-HT2b) receptor antagonist	Approval	https://conductscience.org/library/genes/3357	Drugs and targets
SLC6A4	Sodium-dependent serotonin transporter	3	Serotonin transporter inhibitor	Approval	https://conductscience.org/library/genes/6532	Drugs and targets

1 to 10 of 77

See all 77 targets

Trials98

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 7 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00550238	A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis	Phase 3	459	2019-06-24	Parkinson's Disease Psychosis	PIMAVANSERIN	Its record names the disease	ClinicalTrials.gov
NCT05227703	A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia	Phase 2	391	2025-10-28	Schizophrenia	EMRACLIDINE	Its record names the disease	ClinicalTrials.gov
NCT00477672	A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis	Phase 3	298	2014-03-26	Parkinson's Disease Psychosis	PIMAVANSERIN	Its record names the disease	ClinicalTrials.gov
NCT01438060	Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type	Phase 3	232	2012-03-05	Dementia, Alzheimer Type	ARIPIPRAZOLE	Its record names the disease	ClinicalTrials.gov
NCT02035553	A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis	Phase 2	181	2017-10-25	Alzheimer's Disease Psychosis	PIMAVANSERIN	Its record names the disease	ClinicalTrials.gov
NCT00748566	One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome	Phase 4	172	2013-06-19	Schizophrenia and Disorders With Psychotic Features	ZIPRASIDONE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00281320	Study of Asenapine in Elderly Subjects With Psychosis (A7501021)(P05717)	Phase 3	122	2010-09-09	Psychosis	ASENAPINE MALEATE	Its record names the disease	ClinicalTrials.gov
NCT00125138	Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's Disease	Phase 2	90	2011-06-17	Parkinson's Disease, Psychotic Disorders	MELPERONE	Its record names the disease	ClinicalTrials.gov
NCT02006628	A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder	Phase 2	88	2019-07-26	Schizophrenia, Schizophrenia-related Psychotic Disorder	CANNABIDIOL	Its record names the disease	ClinicalTrials.gov
NCT04559529	Pharmacological Modulation of Hippocampal Activity in Psychosis 2	Phase 2	62	2024-02-05	Schizophrenia; Psychosis	LEVETIRACETAM	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 98

See all 98 trials

Comparisons in its trials14

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Pimavanserin 40 mg vs Placebo: deaths from any cause	4 of 90	4 of 91	181	NCT02035553	Trial comparisons
Pimavanserin 40 mg vs Placebo: serious adverse events	15 of 90	10 of 91	181	NCT02035553	Trial comparisons
Asenapine 2-10 mg Twice Daily (BID) vs Asenapine 5-10 mg BID: Number of Participants Who Discontinued Because of an Adverse Event	12 of 61	9 of 61	122	NCT00281320	Trial comparisons
Asenapine 2-10 mg Twice Daily (BID) vs Asenapine 5-10 mg BID: Number of Participants Who Experienced an Adverse Event	44 of 61	44 of 61	122	NCT00281320	Trial comparisons
Asenapine 2-10mg BID vs Asenapine 5-10mg BID: serious adverse events	6 of 61	3 of 61	122	NCT00281320	Trial comparisons
GWP42003 1000 mg/Day vs Placebo: serious adverse events	0 of 43	1 of 45	88	NCT02006628	Trial comparisons
Novel Lipid Formulation Cannabidiol vs Standard Formulation Cannabidiol: deaths from any cause	0 of 14	0 of 14	28	NCT05032807	Trial comparisons
Novel Lipid Formulation Cannabidiol vs Standard Formulation Cannabidiol: serious adverse events	0 of 14	0 of 14	28	NCT05032807	Trial comparisons
Olanzapine Group vs Clozapine Group: serious adverse events	1 of 13	2 of 12	25	NCT00001656	Trial comparisons
Cannabidiol, Then Placebo vs Placebo, Then Cannabidiol: deaths from any cause	0 of 8	0 of 10	18	NCT02504151	Trial comparisons

1 to 10 of 14

See all 14 comparisons in its trials

Papers from its trials55

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
21755540	RESULT	1	PubMed
16818861	RESULT	1	PubMed
10084637	RESULT	1	PubMed
42656845	DERIVED	1	PubMed
42629434	DERIVED	2	PubMed
41640857	DERIVED	1	PubMed
41384764	DERIVED	1	PubMed
41326319	DERIVED	1	PubMed
40940558	DERIVED	1	PubMed
39771516	DERIVED	1	PubMed

1 to 10 of 55

See all 55 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005485

GET https://conductscience.org/api/diseases/v1/MONDO_0005485/drugs?page=2

API reference For AI assistants